close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Stallergenes Greer

Staloral® Birch Phase III Study Successfully Meets Primary Endpoint, Demonstrating Efficacy in Children and Adolescents
From Stallergenes Greer
Via Business Wire
Stallergenes Greer and Nuance Pharma Enter Exclusive Long-term Partnership for Actair® Sublingual Immunotherapy Tablet for the Treatment of House Dust Mite Allergy in China
From Stallergenes Greer
Via Business Wire
Stallergenes Greer Announces Palforzia® Featured on “The Balancing Act” Airing on Lifetime TV
From Stallergenes Greer
Via Business Wire
Stallergenes Greer Showcases Developments in Respiratory and Food Allergy Care at EAACI 2025
From Stallergenes Greer
Via Business Wire
Positive Adherence Impact of IPUMP® Connected Assistant for Sublingual Liquid Allergen Immunotherapy Treatment
From Stallergenes Greer
Via Business Wire
Stallergenes Greer Announces Appointment of Andreas Amrein as Chief Executive Officer
From Stallergenes Greer
Via Business Wire
Palforzia® Oral Immunotherapy for the Treatment of Peanut Allergy Now Available in the U.S. for Pediatric Ages 1 Through 3 Years
From Stallergenes Greer
Via Business Wire
European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy
From Stallergenes Greer
Via Business Wire
Science Awards for Allergy 2025: Call for Applications
From Stallergenes Greer
Via Business Wire
Positive CHMP Opinion for the Extension of Indication of Palforzia® for the Treatment of Toddlers With Confirmed Peanut Allergy
From Stallergenes Greer
Via Business Wire
FDA Approves U.S. Pediatric Indication Extension for Palforzia® Oral Immunotherapy for the Treatment of Peanut Allergy
From Stallergenes Greer
Via Business Wire
Stallergenes Greer Showcases New Data for Food and Respiratory Immunotherapy at 2024 EAACI Congress
From Stallergenes Greer
Via Business Wire
Stallergenes Greer Foundation Announces Winners of 2023 Science Awards for Allergy
From Stallergenes Greer
Via Business Wire
Stallergenes Greer Publishes in the Lancet Regional Health-Europe Landmark EfficAPSI Real-world Study Confirming Significant Benefit of Its Liquid Sublingual AIT on the Onset and Progression of Allergic Asthma
From Stallergenes Greer
Via Business Wire
Stallergenes Greer Announces Publication of Positive Results for PALFORZIA® Phase 3 Study in Peanut-allergic Children Aged 1 to 3 Years
From Stallergenes Greer
Via Business Wire
Stallergenes Greer Announces Global Agreement With Nestlé Regarding the Peanut Allergy Oral Immunotherapy Treatment Palforzia®
From Stallergenes Greer
Via Business Wire
Stallergenes Greer Showcases Clinical Relevance and Persisting Benefits of Its Allergen Immunotherapy Treatments at 2023 EAACI Congress
From Stallergenes Greer
Via Business Wire
Stallergenes Greer Initiates a European Paediatric Phase III Study With Staloral® Birch
From Stallergenes Greer
Via Business Wire
Stallergenes Greer Foundation to Foster Innovation and Precision Medicine in the Field of Allergy
From Stallergenes Greer
Via Business Wire
Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment on the Onset and Worsening of Asthma in Patients With Allergic Rhinitis
From Stallergenes Greer
Via Business Wire
Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy With Imperial College London Research Collaboration
From Stallergenes Greer
Via Business Wire
Stallergenes Greer and Aptar Pharma Announce Partnership to Develop Novel Connected Device for Allergen Immunotherapy Treatment Delivery
From Stallergenes Greer
Via Business Wire
Stallergenes Greer Launches CORAP (Community for Research in Allergic Patients) Research Programme
From Stallergenes Greer
Via Business Wire
Stallergenes Greer and Alyatec Announce Research Collaboration to Advance Precision Medicine in Allergen Immunotherapy
From Stallergenes Greer
Via Business Wire
Stallergenes Greer: Alustal®, the Company’s Subcutaneous Allergen Immunotherapy Treatment (SCIT) Now Available
From Stallergenes Greer
Via Business Wire
Positive Outcome of European Decentralised Registration Procedure for Stallergenes Greer’s Sublingual House Dust Mite Allergen Immunotherapy Tablet
From Stallergenes Greer
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today